MUSK and myasthenia gravis: Nonetheless, our finding that MuSK-antibody myasthenia gravis is not associated with a higher risk for refractory myasthenia gravis most likely reflects recent changes in treatment practices, which favor early treatment with rituximab leading to improved outcomes in this subgroup [20].